Applicant(s): Sanders et al.

Serial No. Unknown (Parent Serial No. PCT/US2003/17577)

Filed: Herewith (Parent: 4 June 2003)

For: IMPROVED PSEUDOTYPED RETROVIRUSES

Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the aboveidentified application:

Listing of Claims

- 1. (Original) A pseudotyped retrovirus comprising recombinant RNA associated with a retroviral core surrounded by a lipid bilayer having disposed therein a glycoprotein comprising a modified *O*-glycosylation region, the recombinant RNA comprising (i) a nucleotide sequence defining a selected biomolecule intended for delivery to a target cell, and (ii) retroviral control elements for packaging, reverse transcription and integration of the retrovirus into a target cell.
- 2. (Original) The pseudotyped retrovirus of claim 1 wherein the retroviral core and control elements are from Moloney murine leukemia virus (Mo-MuLV).
- 3. (Currently Amended) The pseudotyped retrovirus of claim [[3]] $\underline{1}$ wherein the retroviral core and control elements are from a lentivirus.
- 4. (Original) The pseudotyped retrovirus of claim 1 wherein the lentivirus is feline immunodeficiency virus (FIV), human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV) or equine infectious anemia virus (EIAV).
- 5. (Original) The pseudotyped retrovirus of claim 1 wherein the glycoprotein is a filovirus glycoprotein.
- 6. (Original) The pseudotyped retrovirus of claim 1 wherein the selected biomolecule is a protein.

Preliminary Amendment

Applicant(s): Sanders et al.

Serial No. Unknown (Parent Serial No. PCT/US2003/17577)

Filed: Herewith (Parent: 4 June 2003)

For: IMPROVED PSEUDOTYPED RETROVIRUSES

7. (Original) The pseudotyped retrovirus of claim 1 wherein the selected biomolecule is a bioactive RNA.

- 8. (Original) The pseudotyped retrovirus of claim 1 having a transduction efficiency into target cells of at least 2-fold higher than a retrovirus pseudotyped with the wild-type glycoprotein.
- 9. (Original) A pseudotyped retrovirus comprising recombinant RNA associated with a retroviral core surrounded by a lipid bilayer having disposed therein an Ebola glycoprotein comprising a modified *O*-glycosylation region, the recombinant RNA comprising (i) a nucleotide sequence defining a selected biomolecule intended for delivery to a target cell, and (ii) retroviral control elements for packaging, reverse transcription and integration of the retrovirus into a target cell.
- 10. (Original) The pseudotyped retrovirus of claim 9 wherein the Ebola glycoprotein contains a deletion of nucleotides 309 to 489 in SEQ ID NO:1.
- 11. (Original) The pseudotyped retrovirus of claim 10 wherein the retroviral core and control elements are from Mo-MuLV retrovirus.
- 12. (Original) The pseudotyped retrovirus of claim 10 wherein the retroviral core and control elements are from a lentivirus.
- 13. (Original) A pseudotyped retrovirus pseudotyped with a glycoprotein comprising a modified *O*-glycosylation region, the pseudotyped retrovirus having a transduction efficiency into a target cell of at least 2-fold higher than a retrovirus pseudotyped with the wild-type glycoprotein.
- 14. (Original) A recombinant virus producer cell comprising gag, pro and pol nucleotide

Preliminary Amendment

Applicant(s): Sanders et al.

Serial No. Unknown (Parent Serial No. PCT/US2003/17577)

Filed: Herewith (Parent: 4 June 2003)

For: IMPROVED PSEUDOTYPED RETROVIRUSES

sequences and a nucleotide sequence encoding a glycoprotein comprising a modified *O*-glycosylation region.

- 15. (Original) The recombinant virus producer cell of claim 14 wherein the glycoprotein is an Ebola glycoprotein containing a deletion of nucleotides 309 to 489 in SEQ ID NO:1.
- 16. (Original) The recombinant virus producer cell of claim 15 which is a NIH 3T3 cell, COS cell, Madin-Darby canine kidney cell, human embryonic 293T cell or any cell derived therefrom.
- 17. (Original) A method for making a pseudotyped retrovirus comprising supplying a recombinant RNA to the recombinant virus producer cell of claim 12, wherein recombinant RNA comprises (i) a nucleotide sequence defining a selected biomolecule intended for delivery to a target cell, and (ii) retroviral control elements for packaging, reverse transcription and integration of the retrovirus into a target cell, under conditions such that pseudotyped retrovirus is produced.
- 18. (Original) The method of claim 17 wherein supplying the recombinant RNA to the producer cell comprises introducing a DNA encoding the recombinant RNA into the producer cell.
- 19. (Original) The method of claim 17 supplying the recombinant RNA to the producer cell comprises introducing the recombinant RNA into the cell.
- 20. (Original) A method for transducing a target cell comprising contacting a target cell with the pseudotyped retrovirus of claim 1.
- 21. (Original) The method of claim 18 wherein the target cell is an insect cell, a bird cell, a fish cell or a mammalian cell.
- 22. (Original) The method of claim 19 wherein the target cell is a human cell.

Applicant(s): Sanders et al.

Serial No. Unknown (Parent Serial No. PCT/US2003/17577)

Filed: Herewith (Parent: 4 June 2003)

For: IMPROVED PSEUDOTYPED RETROVIRUSES

- 23. (Original) The method of claim 18 wherein the cell is in vivo, ex vivo, or in cell culture.
- 24. (Original) The method of claim 18 wherein the selected biomolecule is a protein, and wherein the transduced target cell expresses the protein.
- 25. (Original) The method of claim 18 wherein the selected biomolecule is a bioactive RNA, and wherein the transduced target cell produces the bioactive RNA.